Portal de Periódicos da CAPES

Primary CD56 positive lymphomas of the gastrointestinal tract

2001; Wiley; Volume: 91; Issue: 3 Linguagem: Inglês

10.1002/1097-0142(20010201)91

1097-0142

Chor Sang Chim, Wing Y. Au, Tony W.H. Shek, Judy W.C. Ho, Carolyn Choy, Edmond S.K., Hiu Ming Tung, Raymond Liang, Yok‐Lam Kwong,

Immune Cell Function and Interaction

BACKGROUND Primary CD56 positive lymphoma of the gastrointestinal (GI) tract is rare. Genotypically, these tumors can be classified into natural killer (NK)-like T-cell lymphoma or NK cell lymphoma by the presence or absence of T-cell receptor (TCR) gene rearrangement. However, they have a considerable degree of morphologic and immunophenotypic overlap, making a definitive diagnosis difficult. METHODS The clinicopathologic features of three patients with primary CD56 positive lymphoma of the small and large bowel are presented. This is followed by a review of the English literature from 1966 to the present. RESULTS All patients had CD56 posistive/CD3ϵ positive disease on paraffin section. Two patients were positive for Epstein–Barr virus-encoded early nuclear RNAs (EBER) according to in situ histochemistry results and were negative for TCR gene rearrangement, consistent with primary NK lymphoma of the GI tract. The other patient was EBER negative with rearranged TCR, consistent with NK-like T-cell lymphoma. There was no clinical or histologic evidence of enteropathy in any of the patients. The major presenting symptoms included fever, weight loss, and intestinal perforation. All patients died between 1 week and 6 months after diagnosis despite undergoing surgery and intensive chemotherapy. CONCLUSIONS These results, together with a literature review, suggest that primary NK cell lymphoma of the GI tract may be considered a distinct clinicopathologic entity. Both primary NK and NK-like T-cell lymphoma pursue an aggressive clinical course. EBER and TCR gene rearrangement are useful in distinguishing NK cell lymphoma from NK-like T-cell lymphoma, particularly when frozen tissue is not available for immunophenotyping. Cancer 2001;91:525–33. © 2001 American Cancer Society.